The Effect of Buspirone on Prolactin and Growth Hormone Secretion in Man

Herbert Y. Meltzer*, Rachel Flemming, Alan Robertson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

Buspirone hydrochloride, a compound with novel chemical structure, has been reported to be anxiolytic in man. Its mechanism of action as an anxiolytic is unknown, but preclinical studies have shown that it produces effects consistent with both a dopamine agonist and antagonist. In man, buspirone hydrochloride at doses of 30,60, and 90 mg orally significantly elevated plasma prolactin (PRL) and growth hormone (GH) concentrations. The apparent increase in PRL secretion was dose dependent, but that of GH was not. The increase in PRL secretion could be due to a dopamine antagonist effect at the pituitary gland. A dopamine agonist action at hypothalamic dopamine receptors could account for the increase in GH secretion. Benzodiazepine anxiolytic drugs also increase serum GH levels in man, by a mechanism that has not been clearly established. It may be that buspirone and benzodiazepine drugs stimulate GH secretion by a common mechanism that is related to their anxiolytic actions.

Original languageEnglish (US)
Pages (from-to)1099-1102
Number of pages4
JournalArchives of general psychiatry
Volume40
Issue number10
DOIs
StatePublished - Oct 1983

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'The Effect of Buspirone on Prolactin and Growth Hormone Secretion in Man'. Together they form a unique fingerprint.

Cite this